Boston Scientific Corporation $BSX Shares Sold by Ninety One UK Ltd

Ninety One UK Ltd lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 99.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 17,658 shares of the medical equipment provider’s stock after selling 3,484,327 shares during the period. Ninety One UK Ltd’s holdings in Boston Scientific were worth $771,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. State of Alaska Department of Revenue lifted its stake in Boston Scientific by 11.8% during the third quarter. State of Alaska Department of Revenue now owns 162,750 shares of the medical equipment provider’s stock worth $7,104,000 after purchasing an additional 17,115 shares during the period. Chiron Capital Management LLC boosted its holdings in Boston Scientific by 8.4% during the third quarter. Chiron Capital Management LLC now owns 20,601 shares of the medical equipment provider’s stock valued at $899,000 after purchasing an additional 1,600 shares in the last quarter. WealthPlan Investment Management LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $203,000. Mainsail Asset Management LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $234,000. Finally, Nvwm LLC grew its stake in shares of Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 542 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $44.17 on Friday. The firm has a market cap of $64.02 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average price is $46.16 and its two-hundred day moving average price is $49.80.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BSX. Weiss Ratings reissued a “sell (d+)” rating on shares of Boston Scientific in a report on Friday, October 2nd. Canaccord Genuity Group decreased their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, September 17th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Finally, Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $68.23.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last three months. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.